报告题目
1: 
 
Shoot for the moon, landed on Mars: the mechanistic study of neuroprotective peptide CN-105
报告题目
2: 
 
Scalable production of therapeutic exosomes: progress and challenges
 
报
 
告
 
人：王伊
 
副研究员，光武惠文生物科技（北京）有限公司
 Excerene Biosciences Co. Ltd.
邀
 
请
 
人：周丛照教授
报告时间：
2020
年
10
月
10
日（周一）上午
 10
：
00 - 12
：
00
报告地点：生物楼329A会议室
报告人简介：王伊副研究员本科于
2006
年毕业于中国科学技术大学生命科学学院，随后在美国
Duke University
生物化学系学习并取得博士学位。他在
Duke
就读期间参与了新型脑卒中治疗药物
CN-105
的研发工作。回国后，王伊博士先后在中科院生物物理所、军事医学研究院、蛋白质药物国家工程研究中心工作，并于
2018
年
10
月创立
Excerene Biosciences Co. Ltd, 
基于干细胞外泌体技术和
AI
药物设计技术开发新型治疗药物。目前已有两个新药品种获得
IND
，研究发表在《
JACS
》、《
Small
》、《
Sensors and Actuators B
》等期刊上。
报告简介
: 
1) CN-105 is a clinical-stage neuroprotective drug that is being evaluated in several clinical trials of intracranial hemorrhage and ischemic stroke in China, US and Singapore. The drug was initially designed as an ApoE-mimetic peptide, while its true mechanism of action remains elusive. Not until recently have we zeroed in the molecular target of CN-105. Here we recapitulate a 7-yr target identification study of CN-105, and share the lessons learned along the way. 2) Extracellular vesicle (EV), especially exosome, is a unique type of natural nanoparticle that posesses great promises in both targeted drug delivery and cell-free cell therapy. It has become a field of intensive research and a hot spot for venture capitals. One limitation of current technology of therapeutic exosome is a lack of scalability and compatibility with current GMP production facility of biological drugs. At Excerene Biosciences, we are striving to develop a scalable and GMP-compatible manufacture process of therapeutic exosomes from both cell culture supernatant and bovine milk. Here we report current progress and challenges in this field.